Objective: Early cannulation arteriovenous grafts (ecAVGs) are proposed as an alternative to tunneled central venous catheters (TCVCs) in patients requiring immediate vascular access for hemodialysis (HD). We compared bacteremia rates in patients treated with ecAVG and TCVC.
Arteriovenous fistulas (AVFs) are the vascular access of choice for patients requiring hemodialysis (HD). Tunneled central venous catheters (TCVCs) are recommended only as an option of necessity. 1, 2 In practice, AVF usage is limited by delays in operative planning, maturation time, and a failure to mature rate approaching 60% in some randomized trials. 3 If HD is required before the AVF is functionally mature, an alternative access (generally TCVC) is required. 1, 2 A recent study in Scotland of 2666 patients revealed a twofold to threefold increased risk in all-cause mortality and a sevenfold increase in death from septicemia with the use of TCVCs. 4 The complications of vascular access are responsible for >20% of hospitalizations in patients on HD and account for 33% of all in-patient renal bed usage. [5] [6] [7] It therefore follows that a strategy of TCVC avoidance is likely to have significant benefits for individual patients and health care providers. Arteriovenous grafts (AVGs) provide an alternative means of vascular access. AVGs have traditionally been used only when all other native venous options have been exhausted. However, the recent development of early cannulation AVGs (ecAVGs) now allows grafts to be considered as an alternative to a TCVC in patients requiring vascular access imminently. 8, 9 The benefits and limitations of an AVG lie somewhere between those of a TCVC and an AVF: they require significantly greater initial outlay in surgical expertise, time, and material cost 10 but have infection and complication rates lower than a TCVC. 11, 12 Culture-proven bacteremia rates for TCVCs are 1.77/1000 catheter days compared with 0.6/ 1000 dialysis days for an AVG and 0.3/1000 dialysis days for an AVF. 11, 12 Primary patency rates for AVGs range from 40% to 60% at 1 year. 13 However, with aggressive management of thrombosis, secondary patency rates as high as 90% at 1 year can be achieved.
14 Between 30% and 35% of patients who need to start HD are referred for access creation <90 days before the date that they need to start HD, leaving insufficient time for planning, surgery, and maturation of an AVF. 15, 16 In the United Kingdom, only 40% of patients commence HD through an AVF. 15 The ecAVG may have a role in these incident "crashlander" patients, in whom there has not been sufficient time to create and mature an AVF and avoid the need for TCVC.
In recent years, a number of case series, including one from our institution, have highlighted the potential role of an ecAVG as an alternative to a TCVC in patients requiring urgent vascular access for HD. 8, 9 Results have been promising, albeit in small patient numbers. Observational data suggests that such a strategy could deliver a cost savings of nearly £1000 per patient after 6 months. 10 We therefore designed a randomized controlled trial comparing ecAVGs vs TCVCs in patients requiring urgent vascular access for HD. We hypothesized that ecAVGs would result in a lower bacteremia rate than TCVCs and could potentially deliver cost savings.
METHODS

Ethics
The study protocol was reviewed and approved by the West of Scotland Research Ethics Committee 4 (13/WS/ 0187). All trial procedures were in concordance with the Declaration of Helsinki, 1975 Helsinki, (revised 2000 . All participants provided written informed consent. A Trial Steering Committee was convened before the start of the study and annually to evaluate data and safety. All serious adverse events, defined as death or life-threatening sepsis, were reported to the Research Ethics Committee.
Study design and participants
This prospective single-center randomized controlled trial was performed in the Department of Renal Surgery, Western Infirmary, Glasgow. The trial protocol has been previously published. 17 The study was inclusive. All patients aged $18 years with established renal failure who required urgent vascular access for HD (ie, needed for HD #48 hours for referral) were eligible to participate. Patients were excluded if they had a recent myocardial infarction (<4 weeks), active systemic sepsis, no anatomically suitable vessels for ecAVG based on preoperative imaging, anticipated life expectancy <3 months, an existing AVF thought likely to be useable #2 weeks, if they lacked capacity to provide informed consent, or declined to participate in the study.
Randomization
Patients were randomly assigned (1:1) by a computergenerated randomization sequence and sealed envelopes to receive a TCVC with or without (þ/À) an AVF or an ecAVGþ/ÀAVF. Masking the allocation of treatment to patient, surgeon, or study investigator was not possible because of the nature of the treatment and any subsequent interventions.
Procedures
Preoperative planning. All patients underwent duplex ultrasound imaging of both arms (and legs where no suitable upper limb option was determined). The venous and arterial trees were both assessed, and a preoperative plan was made to site both ecAVG and native AVF (if possible). A minimum arterial cross-sectional diameter of 2 mm was deemed necessary to sustain an AVF or ecAVG. Venous diameters of 2 mm at the wrist and 3 mm at the elbow were considered suitable for an AVF (or forearm loop graft). A patent basilic/axillary artery measuring at least 3 mm was deemed necessary to site the venous outflow of an ecAVG. Care was taken in the choice of anatomical site for the ecAVG to preserve all possible sites for future autologous access, with the site of native AVF favored distally in the nondominant arm. An ecAVG was placed to accommodate optimal AVF placement. For example, a native left radiocephalic fistula and right brachioaxillary graft was favored in a lefthanded patient with good native vessels and no previous vascular access, whereas revision of an existing occluded left brachiocephalic fistula using an interposition ecAVG and contralateral elbow AVF would be considered in an elderly patient with poor vessels and occluded existing AVF. TCVCD/LAVF strategy. The TCVCþ/ÀAVF strategy reflected standard practice at our institution, with TCVC insertion performed by a radiologist or nurse specializing in TCVC insertion. One dose of intravenous vancomycin was administered before catheter replacement.
Tunneled Ash Split (Medcomp, Harleysville, PA) 14F double-lumen polyurethane HD catheters were inserted, with 280 mm (left) or 320 mm (right) catheters inserted by a Seldinger technique under image guidance. A standard protocol for catheter care was used throughout the study period. This demanded complete sterile precautions during insertion and manipulation with an assistant or a no-touch technique to manipulate the hub of the catheter. Full aseptic technique was used to commence and disconnect from dialysis. The catheter hubs were wrapped with 70% isopropyl alcohol wipes to maintain asepsis and permit no-touch initiation and discontinuation of dialysis. At the end of dialysis, the skin was cleaned with chlorhexidine before application of a new sterile dressing, and an interdialytic lock with TauroHep500 (TauroPharm GmbH, Waldbüt-telbrunn, Germany) was used.
The first HD was performed by trained nursing staff within the InPatient Renal Unit. Subsequent dialysis sessions occurred at regional outpatient dialysis units in the West of Scotland.
The ecAVGD/LAVF technique. Patients randomised to receive an ecAVGþ/ÀAVF underwent anesthetic assessment and surgery #24 hours of randomization, wherever possible. Prophylactic vancomycin, 1 g intravenously (or teicoplanin if the patient was allergic to vancomycin), was given preoperatively. All ecAVG implantations were performed by a single operating surgeon under a supraclavicular block or general anesthetic.
Alcoholic Betadine (Purdue Pharma LP, Stamford, Conn) was used for cleaning the skin, and an Ioban skin covering (3M Healthcare, Bracknell, UK) was applied to maintain strict asepsis. The vessels were exposed and controlled in a standard fashion. Standard Kelly-Wick tunnelers were used to tunnel the Acuseal graft (W. L. Gore Associates, Flagstaff, Ariz) in the subcutaneous fat. A 4-cm longitudinal venotomy was performed, and the graft was spatulated at the venous end in an attempt to minimize venous stenosis. A 4-mm to 6-mm arteriotomy was made to accommodate the graft. Arterial and venous anastomoses were performed using continuous 5-0 Prolene (Ethicon, Somerville, NJ). Collatamp (Tribute Pharmaceuticals, Milton, ON, Canada) was inserted before wound closure to minimize the risk of infection. Drains were not routinely used.
First cannulation of the ecAVG was performed by trained dialysis nursing staff in the InPatient Renal Unit. The timing of cannulation was determined by clinical need, with no minimum period after surgery. Sharp needles (17 gauge), low flows (200 to 250 mL/min), and minimal heparin were used for the first cannulation. Full aseptic technique was used for cannulation, and direct pressure was applied at the needle sites for at least 10 minutes after the needles were removed. These same techniques were used for the first 2 weeks of cannulation. Thereafter, higher flow rates were permitted if necessary to achieve adequate dialysis clearance. Patients were discharged after at least two successful cannulations of the ecAVG. Maintenance dialysis was performed at Outpatient Dialysis Units in the West of Scotland.
All patients completed 1 week of intravenous vancomycin postoperatively. Heparin, warfarin, and antiplatelet agents were administered at the discretion of the operating surgeon. All patients who re-presented with thrombotic complications were anticoagulated with warfarin unless contraindicated. All ecAVGs underwent surveillance ultrasound imaging and angiography at 3 months and at 3-month intervals thereafter. Any stenosis (on either imaging modality) in the context of access dysfunction was considered clinically significant, prompting angioplasty with or without stenting (for recurrent lesions). In the event of thrombosis, aggressive attempts at declotting were made by a combined surgical and radiologic approach.
Autologous AVF creation. Patients in both treatment arms also underwent creation of an autologous AVF (if this was anatomically possible). In the ecAVG cohort, this was performed at the same time as the ecAVG, if possible; otherwise, every effort was made to provide the patient with the opportunity of AVF creation on the next available operating theater list (#1 to 2 weeks). The ecAVG/TCVC was used for HD until the AVF was mature enough to cannulate. The decision to perform the first cannulation of the AVF was taken by the clinical team (normally w6 weeks after creation) after clinical assessment by the Vascular Access Co-ordinator.
Once established on dialysis via an AVF, the fate of a redundant ecAVG was decided after discussion between the patient and surgical team. The ecAVG was left in situ in most patients, but on occasion was removed or ligated if required or wished. The surgical team removed TCVCs after six successful AVF cannulations, as is standard practice.
Follow-up
Patients were reviewed at 1 day, 7 days, and at 3 and 6 months. In addition, data on access-related complications were recorded prospectively at each dialysis session. In addition to demographics and operative details, data were collected on perioperative complications, date of first access use, treatment delays, requirement for antibiotics or urokinase infusions, or both, access complications (bacteremia, local infection, thrombosis, stenosis, poor flows), and reinterventions (new access creation or insertion, thrombectomy, angioplasty). Quality of life (QoL) data were collected at entry to the study and at 6 months of follow-up.
Outcomes
The primary outcome measure was culture-proven bacteremia at 6 months, defined according to the Centers for Disease Control and Prevention as laboratory-confirmed positive peripheral blood cultures in association with clinical symptoms of access infection or failure to identify infection at a secondary site. 18 Secondary outcomes were local infection, thrombosis, stenosis, reinterventions (including thrombectomy, antibiotics, and urokinase locks), additional vascular accesses, QoL, whether the access provided a "personal vascular access solution," 9 length of inpatient hospital stay, and death at 6 months. Local infection was also defined according to Centers for Disease Control and Prevention definitions as proven (laboratory-confirmed positive cultures from local swabs) or suspected (clinical signs and symptoms but no positive culture). 18 Thrombosis was defined clinically as the absence of thrill or bruit from a graft and inability to dialyze via it, or the inability to dialyze via flush, or to aspirate from a TCVC. Health-related QoL (HR-QoL) was evaluated using the EuroQoL-5D (EQ-5D) questionnaire. 19 Sample size calculation We postulated a reduced incidence of systemic bacteremia in the ecAVGþ/ÀAVF group. Using previously published bacteremia rates for TCVCs and ecAVG in our own institution, 9, 10 we calculated that 53 patients would be needed in each group to provide 80% power to detect a reduction in the incidence of systemic bacteremia from 24% to 5% at 6 months of follow-up with an a ¼ .05. To account for attrition/loss to follow-up of 10%, we aimed to recruit 118 patients (n ¼ 59 per arm).
Statistical analysis
All analysis was performed on an intention-to treat basis. Any patient randomized but who withdrew from the study before the procedure was replaced by another patient but continued to be monitored on an intention-totreat basis. Normal distribution of data was confirmed by limited skewness and kurtosis. Results for continuous variables are reported as mean 6 standard deviation (SD) or median (interquartile range [IQR] ). Accessrelated bacteremia rates are presented as a proportion of the total population (and risk ratio) and as a rate per 1000 access days. Having confirmed normal distribution, treatment groups were compared using t-tests for continuous variables and c 2 tests for categoric variables.
In additionally, a cost-effectiveness analysis was performed (B.M.) to compare the average total treatment costs within each arm. Average costs per patient were derived from direct resource utilization data along with the unit costs for each procedure. Unit costs were obtained from National Health Service Reference Costs . 20, 21 All costs (eg, bed days, material costs of ecAVG/TCVC, or antibiotics) were derived directly from those observed in the study. An intention-to-treat analysis was conducted with the perspective of the provider. Results summarize the average cumulative total costs per patient from trial initiation to 6 months of patient follow-up.
RESULTS
Between December 5, 2013, and February 5, 2015, 121 patients were randomly assigned to the ecAVGþ/ÀAVF group (n ¼ 60) or the TCVCþ/ÀAVF group (n ¼ 61). Thirteen patients (11%) died during the follow-up period. No other patient was lost to follow-up (Fig) . Table I reports baseline characteristics of randomized patients. Thirty-one percent of patients (n ¼ 38) commenced dialysis for the first time, of whom 39% (n ¼ 15) were crashlanders (ie, known to a nephrologist <90 days before starting dialysis). The rest of the patients had previously been on renal replacement therapy via another modality or vascular access that had failed (Table II) . AVF was the ultimate intended vascular access in 62% of patients (n ¼ 75), with the intention of long-term AVG in 33% (n ¼ 40). A total of 52 AVFs in 34 patients were also made during the follow-up period.
The culture-proven bacteremia rate was significantly higher in the TCVCþ/ÀAVF cohort (0.97/1000 catheter days) than in the ecAVGþ/ÀAVF cohort (0.19/1000 access days), with culture-proven bacteremia developing in 16% of patients (n ¼ 10) during the first 6 months in the TCVCþ/ÀAVF arm compared with 3% (n ¼ 2) in the ecAVGþ/ÀAVF arm (risk ratio, 0.2 95% confidence interval, 0.12-0.56; P ¼ .02). Mortality was also higher in the TCVCþ/ÀAVF cohort, at 16% (n ¼ 10) vs 5% (n ¼ 3; risk ratio, 0.3 95% confidence interval, 0.08-0.45; P ¼ .04).
No patient died as a result of access-related complications (including access-related sepsis). One patient in the ecAVGþ/ÀAVF arm died of a perioperative myocardial infarction.
Median waiting time was 6 days (range, 1-21 days) for TCVC insertion and 14 hours (range, 1-168 hours) for ecAVG insertion (P < .001). Twice as many patients in the TCVCþ/À AVF cohort required a bridging temporary catheter than in the ecAVGþ/ÀAVF cohort (49% [n ¼ 30] vs 25% [n ¼ 15]; P ¼ .006). Median hospital length of stay for vascular access (including associated delays) was 4 (IQR, 2-7) days in the ecAVGþ/ÀAVF cohort and 7 (IQR, 3-13) days in the TCVCþ/ÀAVF cohort (P < .0001). Four patients in the ecAVG arm had perioperative complications: myocardial infarction (n ¼ 2), venous hypertension and limb swelling (n ¼ 1), and pseudoaneurysm (n ¼ 1). Attempts at TCVC insertion failed in four patients, and initial attempts at insertion were abandoned in 1 one patient because of flash Table III . Thirty-four episodes of graft thrombosis were observed in 16 patients (27%). Patients in the TCVCþ/ÀAVF arm spent an average of 4.7 days/patient in the hospital for access-related complications compared to 2.7 days/patient in the ecAVGþ/ÀAVF arm (P < .001). The total number of hospital days were reduced in the ecAVGþ/ÀAVF cohort in the 6 months after graft insertion compared with the 6 months before ecAVG insertion (4 [IQR, [3] [4] [5] [6] [7] Initial HR-QoL scores were comparable at entry to the study (total EQ-5D: 67 6 12 vs 67 6 14; P ¼ .89). However at the 6-month follow-up, patients in the ecAVGþ/À AVF cohort had better HR-QoL scores (74 6 18 vs 63 6 16; P ¼ .001).
At the 6-month follow-up, only 23% (n ¼ 14) of patients in the ecAVGþ/ÀAVF arm and 16% (n ¼ 10) of patients in the TCVCþ/ÀAVF arm were dialyzing via an autologous AVF. At the end of the 6-month follow-up, 34 patients were still awaiting further attempts at achieving autologous access. In the ecAVGþ/ÀAVF cohort 50% (n ¼ 30) were still using their ecAVG. In the TCVCþ/ÀAVF arm, 52% (n ¼ 32) of patients were still dialyzing via a TCVC. The ecAVG was deemed to be a "personal vascular access solution" (ie, it was still being used for access, had served as a bridge to AVF maturation or transplantation, or was the vascular access at time of death) in 73% (n ¼ 44) of patients. In the TCVCþ/ÀAVF arm, 69% (n ¼ 42) could consider the initial TCVC to be their personal solution.
At the start of the study, 32 patients (52%) in the ecAVGþ/ÀAVF arm had an AVF planned as their definitive vascular access, of which 8 AVFs (25%) thrombosed immediately, 6 were deemed unsuitable to ever provide dialysis, and 4 required an additional procedure to try to achieve functional patency. Nine of the 14 patients with failed AVF underwent a second attempt at AVF creation during the study follow-up. Only 14 patients (23%) were using their AVF at 6 months. With regards to relative placement of ecAVG and AVF in the 32 patients in whom both were created, 15 were deemed to have a radiocephalic fistula option, 14 a brachiocephalic option, and 3 only had a midforearm or lower limb autologous option at the time of graft placement. A contralateral brachioaxillary graft was placed in 21 patients, an interposition graft (into an otherwise defunct fistula) was placed in 8, forearm loops in 2, and a leg graft in 1. In both the patients with forearm loops, the ecAVG was used to mature an outflow cephalic or basilic vein, which was subsequently used to create an autologous fistula, suitable for immediate cannulation. No autologous access option was lost as a result of the ecAVG, even in the 10 patients whose grafts thrombosed.
There was no significant difference in overall costs per patient at 6 months in the ecAVGþ/ÀAVF compared with the TCVCþ/ÀAVF arm (£11,393 vs £9692; P ¼ .24). Infection-related costs made up the largest proportion of costs in the TCVCþ/ÀAVF arm and were significantly higher than infection costs incurred in the ecAVGþ/À AVF arm (£2011 vs £453; P ¼ .02). Reinterventions made up the largest proportion of costs in the ecAVGþ/ÀAVF arm (average £1042 reintervention costs per patient; Table IV ).
DISCUSSION
The incidence of culture-proven bacteremia in patients requiring urgent vascular access for HD was higher in those dialyzing via a TCVC than in those using an ecAVG. A higher mortality rate was also observed in the TCVCþ/À AVF cohort. The cost analysis found ecAVGs were cost neutral, with the initial outlays and costs of reintervention offset against lower costs conferred from the treatment of sepsis and treatment delays. This is the first randomized controlled trial of TCVCs compared with AVGs; however, there is a significant quantity of observational data supporting the findings of this study.
The higher mortality rate in patients dialyzing via TCVCs is well described. 4, 12, 22 The survival difference between the access modalities emerges early in the life of the vascular access and is only partly attributable to infectious deaths. 4, 6 Recent United States Renal Data System data indicate that cardiovascular and all-cause mortality is higher in patients dialyzing via TCVC. 22 Although no patient in our study died as a result of access-related bacteremia, a clear difference in mortality rates was observed as early as 6 months after insertion of the vascular access. Large observational studies report threefold higher rates of bacteremia for TCVC than for AVG. 11, 12 Data from these population-based studies are inherently vulnerable to selection bias, with frailer, sicker patients more likely to dialyze through a catheter. 6 The magnitude of difference observed in the cohort studies is, however, similar to that observed in our series, adding validity to our results. We acknowledge that most of the reported bacteremia rates for AVGs relate to traditional polytetrafluoroethylene grafts and not ecAVGs. Previously published small case-series of ecAVGs report slightly lower culture-proven bacteremia rates of 0.2 to 0.3 per 1000 access days. 9, 23, 24 The rate of cultureproven bacteremia observed in this study was also lower than previously published in both the ecAVGþ/ÀAVF and TCVCþ/ÀAVF cohorts. We attribute this to good practice, with strict infection control measures used at the time of access insertion and for graft cannulation/catheter care. Most importantly, this study reflects real-world practice with an inclusive recruitment strategy. We have demonstrated the role that ecAVGs can play in an unselected cohort of patients requiring urgent vascular access for HD, making the findings clinically applicable and generalizable to a wide variety of patients. Conversely, however, the population is very heterogenous. It may be that specific subgroups of patients are more likely to benefit from ecAVG/TCVC. One such subgroup of interest is the crashlanders. We anticipated that this would be a study principally of crashlanders; however, less than one-third of patients were actually new starts onto dialysis. De novo dialysis patients pose unique challenges. The National Kidney Foundation Vascular Access report 15 found that 60% of crashlanders still had their TCVC 6 months after commencing dialysis and that AVF maturation rates are poorer in patients already on HD via a TCVC, 25, 26 supporting the adage "start with a line, stay on a line." Optimizing the initial vascular access is essential, because a legacy of bad access decision making may have lifelong implications for patients. For these reasons we hypothesize that the beneficial effects of the ecAVG may be even more marked in the cohort of crashlanders, but this study was not powered to demonstrate this. We observed a high rate of autologous fistula failure, with 2.2 attempts at AVF creation for every successfully matured AVF. This high failure rate is not significantly different from that observed in other randomized trials. Dember et al 3 found that 60% of AVFs remained unsuitable for use 5 months after creation and reflects the difficulties of creating autologous access in a contemporaneous dialysis patient cohort. These patients run the risk of surgical fatigue, with second and subsequent AVFs having lower success rates, long-term catheter use leading to central vein stenosis, and ultimate patient refusal of further perceived futile attempts at vascular access. 16, 27 Although the high thrombosis rate of AVGs is well recognized, 13, 14 there are good observational data to suggest that the cumulative patency rates of AVGs are at least comparable to AVFs up to 2 years, accounting for the high early primary failure of AVFs. 28,29 Although we do not advocate choosing an AVG over a native AVF, such factors need to be considered in choosing the correct access for the correct patient, particularly if the patient's life expectancy is short. Before embarking on the study, we had concerns that the ecAVG would risk compromising future sites for upper limb autologous access, particularly given the whole premise of the work was to view vascular access planning as a lifetime journey, which was initially inspired by trying to minimize autologous options lost as a result of central vein stenosis from inappropriate TCVC use. We did not find this to be the case, however. Of the 32 patients in whom an ecAVG and AVF were both made, one had a lower limb ecAVG and eight had interposition grafts into an already defunct AVF, so no potential autologous option was compromised. In two patients, a forearm loop ecAVG was actually used to mature the outflow vein for subsequent successful AVF creation.
More than a study of ecAVGs vs TCVCs, we consider this to be a study comparing strategies and approaches to vascular access provision. We have evaluated a change in practice, with a move away from the TCVC as the default to one that considers alternatives to permit catheter avoidance. Such a change in practice requires a concerted, team-based approach to minimize inertia in the system, as evidenced by the fact that, with effort, an ecAVG could be inserted within 14 hours of referral compared with a 6-day waiting time for a TCVC (acknowledging that this may lead to bias with fewer temporary lines inserted in the ecAVGþ/ÀAVF cohort). We adopted an ethos of native primary (with preservation of the best autologous option) and future access planning. No access was placed in a patient without considering what the exit strategy from that access was (ie, a longterm plan). Such a change in approach to vascular access requires a greater integration in care. We observed a shift in service demands away from interventional radiology, which traditionally placed TCVCs in all of these patients, toward surgery, with a greater ownership of complications by the surgical service for patients within the ecAVGþ/ÀAVF cohort. A policy of ecAVG insertion requires flexibility in operative planning and commitment to provide a 24/7 graft thrombectomy service to achieve a catheter-minimization culture. Significant education of nephrology and nursing colleagues is also required to ensure correct cannulation techniques and to minimize graft complications.
CONCLUSIONS
We have demonstrated that a strategy of ecAVGþ/À AVF for patients requiring urgent vascular access for HD reduces the culture-proven bacteremia rate and mortality at 6 months compared with TCVCþ/ÀAVF. The implementation of these findings into clinical practice will necessitate a paradigm shift in thinking towards vascular access, and supports a culture of "Fistula First" rather than "Line Last." Successful vascular access provision requires a team-based approach that incorporates close integration between the prescription of care by nephrologists and the provision of care by surgeons and interventional radiologists. The successful delivery of this philosophy can help patients receive a more optimally tailored and personalized vascular access solution. 
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